ArticleMolecular genetics and metabolism reports2026
Clinical experience with Pegvaliase in phenylketonuria: A retrospective chart review of outcomes, safety, and dosing patterns.
Article in Molecular genetics and metabolism reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phenylketonuria (PKU) is a metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency, resulting in elevated plasma phenylalanine (Phe) levels. Pegvaliase (Palynziq®), pegylated phenylalanine ammonia lyase (PAL), was approved in 2018 to manage Phe levels in adults with PKU. Real-world data on its long-term efficacy and safety are limited. Objective: To evaluate clinical outcomes, dosing patterns, metabolic control, dietary modifications, and safety of pegvaliase treatment in PKU patients. Methods: A retrospective review was conducted on 37 PKU patients treated with pegvaliase between October 2018 and June 2025. Data included demographics, BH4 responsiveness, plasma Phe levels, dosing of pegvaliase, dietary intake, and adverse events (AEs). Results: Of 33 patients with sufficient follow-up, 24 (73%) achieved plasma Phe levels below 360 μmol/L at a mean of 264 ± 199 days. Within 24 months 85% of patients, including both BH4 (sapropterin) responders and non-responders, achieved two consecutive plasma Phe measurements below 360 μmol/L. Dose requirements varied with most patients achieving these target levels on daily pegvaliase injections ranging from 20 to 60 mg. Dietary liberalization was observed with the majority of patients discontinuing medical formula and reaching the protein Dietary Reference Intake (DRI) within roughly 12 months after initiating pegvaliase. Adverse events (AEs) occurred in 88.6% of patients, most commonly injection site reactions, arthralgia, and rashes of varying severity. Six patients experienced anaphylaxis, but none required hospitalization. Conclusions: Pegvaliase effectively improves metabolic control and dietary flexibility in adolescents and adults with PKU, promoting improved nutrition and overall quality of life. Individualized dosing and careful monitoring are essential due to variability in response and frequent AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.